Iain Stuart

Company: VYNE Therapeutics

Job title: Chief Scientific Officer

Seminars:

Developing the First-in-Class Topical “Soft” BET Inhibitor for the Treatment of Non-Segmental Vitiligo 11:30 am

Interrogating the role of the bromodomain and end terminal family of proteins and reviewing in vivo and ex vivo non-clinical efficacy of VYN201 Advancing the application of a soft drug and target tissue strategy to focus on-target effect and mitigate toxicity Reviewing a Phase 1a/b study in healthy volunteers and patients with non-segmental vitiligo to…Read more

day: Day Two Clinical Track AM